SEC ownership of ADARx Pharmaceuticals, Inc.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001802369.

Comparable stake leader

ORBIMED ADVISORS LLC

Disclosed value leader

—

Comparable rows

2/18

Latest evidence

28 Sep 2026

Top shareholders Insider holders Latest transactions
Parsed ownership sources
3/4/5 and 13D/G
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
Largest SEC-reported holder
ORBIMED ADVISORS LLC
Ranking: Comparable ownership first, then disclosed value
Ownership snapshot CIK-linked ownership evidence from parsed SEC filings. 3 signals
Comparable ownership rows
2 of 18
Meaning: Rows with safely comparable ownership %
Latest 13D/G holder
ORBIMED ADVISORS LLC
Source: Latest parsed Schedule 13D/G stake
Latest parsed ownership date
28 Sep 2026
Freshness: Most recent filing date in this holder set
Issuer Names, identifiers, and filing context for this profile. 2 identity fields
Issuer CIK
0001802369
Issuer location
San Diego, CA

Ownership snapshot

Top shareholders of ADARx Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
—
Comparable rows
2/18
Latest evidence
28 Sep 2026
3/4/5 13D/G Lead comparable stake: 14% 16 rows are not safely comparable across share classes. 13D/G row: ORBIMED ADVISORS LLC Showing 1-8 of 18 holder rows.

Quick read

ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 14%.

2 of 18 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership Top 2
ORBIMED ADVISORS LLC 14%
BCLS Fund III Investments, LP 6.3%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 18 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
ORBIMED ADVISORS LLC
3/4/5 13D/G
Director, 10%+ Owner
3/4/5 13D/G
14%
from 13D/G
—
588,235 shares
 — 28 Sep 2026
BCLS Fund III Investments, LP
13D/G
13D/G
6.3%
—
6,728,970 shares
 $0 24 Sep 2026
LAV Biosciences Fund V, L.P.
3/4/5
10%+ Owner
3/4/5
—
class O/S missing
—
11,858,655 shares
 — 28 Sep 2026
LAV Fund VI Opportunities, L.P.
3/4/5
10%+ Owner
3/4/5
—
class O/S missing
—
11,858,655 shares
 — 28 Sep 2026
LAV Fund VI, L.P.
3/4/5
10%+ Owner
3/4/5
—
class O/S missing
—
11,858,655 shares
 — 28 Sep 2026
Zhen Li
3/4/5
President and CEO, Director, 10%+ Owner
3/4/5
—
mixed-class rows
—
6,885,351 shares
mixed-class rows
 — 24 Sep 2026
Simeon George
3/4/5
Director, 10%+ Owner
3/4/5
—
class O/S missing
—
592,593 shares
 — 28 Sep 2026
SR ONE CAPITAL MANAGEMENT, LLC
3/4/5
10%+ Owner
3/4/5
—
class O/S missing
—
592,593 shares
 — 28 Sep 2026
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 04 Oct 2025.

Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value Sell value
Shares: 0 Shares: 0
Window (months) Buy shares Sell shares Buy value Sell value Net value
0-3 0 0 $0 $0 $0
3-6 0 0 $0 $0 $0
6-9 0 0 $0 $0 $0
9-12 0 0 $0 $0 $0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-19 of 19 reporting-owner rows connected to ADARx Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.

Rows
19
Largest Forms 3/4/5 holder
Zhen Li
Net 12M change
$0
Latest report
28 Sep 2026
Name Relationship Holdings Value Past Year Net Change Change % Valuation Report Date
Zhen Li President and CEO, Director, 10%+ Owner Mixed 24 Sep 2026
Carl L. Gordon Director, 10%+ Owner Mixed 28 Sep 2026
Ryan Fisk CFO and CBO Mixed 24 Sep 2026
Alan Robert MacLeod Chief Scientific Officer Mixed 24 Sep 2026
Rui (nmn) Zhu Chief Technology Officer Mixed 24 Sep 2026
Erez Chimovits Director Mixed 28 Sep 2026
Robert William Ackles Chief People Officer Mixed 24 Sep 2026
Mary Tagliaferri Director Mixed 24 Sep 2026
Ying Huang Director Mixed 24 Sep 2026
LAV Biosciences Fund V, L.P. 10%+ Owner Mixed 28 Sep 2026
LAV Fund VI Opportunities, L.P. 10%+ Owner Mixed 28 Sep 2026
LAV Fund VI, L.P. 10%+ Owner Mixed 28 Sep 2026
ORBIMED ADVISORS LLC Director, 10%+ Owner Mixed 28 Sep 2026
OrbiMed Capital GP VII LLC Director, 10%+ Owner Mixed 28 Sep 2026
OrbiMed Israel GP II, L.P. Director, 10%+ Owner Mixed 28 Sep 2026
OrbiMed Advisors Israel II Ltd Director, 10%+ Owner Mixed 28 Sep 2026
SR ONE CAPITAL MANAGEMENT, LLC 10%+ Owner Mixed 28 Sep 2026
Simeon George Director, 10%+ Owner Mixed 28 Sep 2026
OrbiMed Genesis GP LLC Director, 10%+ Owner Mixed 28 Sep 2026

Recent insider transactions for ADARx Pharmaceuticals, Inc.

Showing up to 300 recent insider transactions from the last 12 months.

Insider Symbol Class Transaction % SEC-reported value SEC-reported price Shares Shares owned Date Ownership
Erez Chimovits ADRX Common Stock Purchase 0.67% 61,516 9,292,025 28 Sep 2026 See footnotes
Erez Chimovits ADRX Common Stock Conversion of derivative security 9,230,509 9,230,509 28 Sep 2026 See footnotes
Erez Chimovits ADRX Series C Preferred Stock Conversion of derivative security -100% -256,448 0 28 Sep 2026 See footnotes
Erez Chimovits ADRX Series B-1 Preferred Stock Conversion of derivative security -100% -513,067 0 28 Sep 2026 See footnotes
Erez Chimovits ADRX Series B Preferred Stock Conversion of derivative security -100% -1,333,975 0 28 Sep 2026 See footnotes
Erez Chimovits ADRX Series A Preferred Stock Conversion of derivative security -100% -7,127,019 0 28 Sep 2026 See footnotes
Carl L. Gordon ADRX Common Stock Purchase 7.1% 950,000 14,325,529 28 Sep 2026 See footnotes
Carl L. Gordon ADRX Common Stock Conversion of derivative security 23,255,789 14,025,280 28 Sep 2026 See footnotes
Carl L. Gordon ADRX Series C Preferred Stock Conversion of derivative security -100% -820,635 0 28 Sep 2026 See footnotes
Carl L. Gordon ADRX Series B-1 Preferred Stock Conversion of derivative security -100% -1,282,668 0 28 Sep 2026 See footnotes
Carl L. Gordon ADRX Series B Preferred Stock Conversion of derivative security -100% -3,334,937 0 28 Sep 2026 See footnotes
Carl L. Gordon ADRX Series A Preferred Stock Conversion of derivative security -100% -17,817,549 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Common Stock Purchase 7.1% 950,000 14,325,529 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Common Stock Purchase 7.1% 950,000 14,325,529 28 Sep 2026 See footnotes
ORBIMED ADVISORS LLC ADRX Common Stock Purchase 7.1% 950,000 14,325,529 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Common Stock Purchase 7.1% 950,000 14,325,529 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Common Stock Purchase 7.1% 950,000 14,325,529 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Common Stock Conversion of derivative security 23,255,789 14,025,280 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Common Stock Conversion of derivative security 23,255,789 14,025,280 28 Sep 2026 See footnotes
ORBIMED ADVISORS LLC ADRX Common Stock Conversion of derivative security 23,255,789 14,025,280 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Common Stock Conversion of derivative security 23,255,789 14,025,280 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Common Stock Conversion of derivative security 23,255,789 14,025,280 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series C Preferred Stock Conversion of derivative security -100% -820,635 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series C Preferred Stock Conversion of derivative security -100% -820,635 0 28 Sep 2026 See footnotes
ORBIMED ADVISORS LLC ADRX Series C Preferred Stock Conversion of derivative security -100% -820,635 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series C Preferred Stock Conversion of derivative security -100% -820,635 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series C Preferred Stock Conversion of derivative security -100% -820,635 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series B-1 Preferred Stock Conversion of derivative security -100% -1,282,668 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series B-1 Preferred Stock Conversion of derivative security -100% -1,282,668 0 28 Sep 2026 See footnotes
ORBIMED ADVISORS LLC ADRX Series B-1 Preferred Stock Conversion of derivative security -100% -1,282,668 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series B-1 Preferred Stock Conversion of derivative security -100% -1,282,668 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series B-1 Preferred Stock Conversion of derivative security -100% -1,282,668 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series B Preferred Stock Conversion of derivative security -100% -3,334,937 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series B Preferred Stock Conversion of derivative security -100% -3,334,937 0 28 Sep 2026 See footnotes
ORBIMED ADVISORS LLC ADRX Series B Preferred Stock Conversion of derivative security -100% -3,334,937 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series B Preferred Stock Conversion of derivative security -100% -3,334,937 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series B Preferred Stock Conversion of derivative security -100% -3,334,937 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series A Preferred Stock Conversion of derivative security -100% -17,817,549 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series A Preferred Stock Conversion of derivative security -100% -17,817,549 0 28 Sep 2026 See footnotes
ORBIMED ADVISORS LLC ADRX Series A Preferred Stock Conversion of derivative security -100% -17,817,549 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series A Preferred Stock Conversion of derivative security -100% -17,817,549 0 28 Sep 2026 See footnotes
Orbimed Advisors Llc ADRX Series A Preferred Stock Conversion of derivative security -100% -17,817,549 0 28 Sep 2026 See footnotes
Sr One Capital Management, Llc ADRX Common Stock Purchase 592,593 592,593 28 Sep 2026 See Note 5
Sr One Capital Management, Llc ADRX Common Stock Conversion of derivative security 1,836,469 1,836,469 28 Sep 2026 See Note 4
Sr One Capital Management, Llc ADRX Common Stock Purchase 27% 414,814 1,953,505 28 Sep 2026 See Note 3
Sr One Capital Management, Llc ADRX Common Stock Conversion of derivative security 1,538,691 1,538,691 28 Sep 2026 See Note 3
Sr One Capital Management, Llc ADRX Common Stock Purchase 11.9% 592,593 5,554,094 28 Sep 2026 See Note 2
Sr One Capital Management, Llc ADRX Common Stock Conversion of derivative security 4,961,501 4,961,501 28 Sep 2026 See Note 2
Sr One Capital Management, Llc ADRX Series B-1 Preferred Stock Conversion of derivative security -100% -198,019 0 28 Sep 2026 See Note 4
Sr One Capital Management, Llc ADRX Series B Preferred Stock Conversion of derivative security -100% -1,953,773 0 28 Sep 2026 See Note 4
* marks a reported price that did not pass the local price check.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .